Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

D. Anker, Stefan; Butler, Javed; Usman, Muhammad; Filippatos, Gerasimos; Pedro Ferreira, João; Alcides Bocchi, Edimar; Böhm, Michael; Brunner‐La Rocca, Hans‐Peter; Choi, Dong‐Ju; Chopra, Vijay; Chuquiure‐Valenzuela, Eduardo; Giannetti, Nadia; Esteban Gómez‐Mesa, Juan; Janssens, Stefan; L. Januzzi, James; Ramón González‐Juanatey, José; Merkely, Béla; J. Nicholls, Stephen; V. Perrone, Sergio; L. Piña, Ileana; Ponikowski, Piotr; Senni, Michele; Sim, David; Špinar, Jindřich; Squire, Iain; Taddei, Stefano; Tsutsui, Hiroyuki; Verma, Subodh; Vinereanu, Dragoş; Zhang, Jian; Iwata, Tomoko; Schnee, Janet; Brueckmann, Martina; Pocock, Stuart; Zannad, Faı̈ez

doi:10.1038/s41591-022-02041-5

Public

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Published in Nature Medicine • Dec 1, 2022

Authors:

Stefan D. Anker

Javed Butler

Muhammad Usman

Abstract

Abstract The EMPEROR-Preserved trial showed that the sodium–glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we repo...

Subject

Empagliflozin

Ejection fraction

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!